Peptide Synthesis Market

Global Peptide Synthesis Market Size (2023 to 2028)

The global peptide synthesis market is expected to be worth USD 1261.5 million by 2028 from USD 867.4 million in 2023, growing at a CAGR of 7.78% from 2023 to 2028.

Global Peptide Synthesis Market Share Insights:

• Based on product, the reagent segment dominated the market in 2022.
• Based on technology, the solid-phase peptide synthesis segment held the major share of the global market in 2022.
• Based on end-user, the pharmaceutical and biotechnology companies segment led the market in 2022.
• Based on region, the North American region accounted for the leading share of the global market in 2022.

Impact of COVID-19 on the Peptide Synthesis Market:

The COVID-19 pandemic crisis has a significant impact on the peptide synthesis market. Peptides were used in large amounts for therapeutic purposes during the COVID-19 pandemic and increasingly being developed and researched in the COVID-19 pandemic situation and it is found to be more opportunistic for the treatment of various purposes. As per the report published by the clinicaltrial.gov, more than 100 peptide drugs were developed for the treatment of COVID-19, including 15 synthetic peptides for acute respiratory distress syndrome, where the lung cannot provide the body’s vital organs with enough oxygen and other respiratory illnesses caused by SARC-Cov-2 infection. Peptides were a more beneficial option for the treatment during a pandemic, as they improved interactions, reduced toxicity, and due to their target selectivity. As these peptides were more beneficial during the pandemic for the proper treatment, thus pandemic situation has a significant impact on the peptide synthesis market. 

MARKET DRIVERS:

Technological advancements primarily drive the growth of the peptide synthesis market. The growing technology of automated injection of various chemicals such as membrane enhanced and ligand synthesis increased adoption of peptide synthesis. Automated injection systems make it possible to distribute chemicals and reagents precisely and under control, minimizing human error and increasing process effectiveness. Higher yields and shorter synthesis instances, which are essential for the scalability and economic feasibility of peptide synthesis, can be attained with the aid of this automation. For contemporary research as well as large-scale production, mechanization in peptide synthesis assures uniform and repeatable outcomes. Automated systems can reduce batch-to-batch variability and guarantee trustworthy peptide synthesis by precisely managing the injection variables and reaction conditions.

The rapid adoption of peptides in the pharmaceutical and consumer healthcare industries boosts the growth rate of the peptide synthesis market. Peptides have numerous applications in the therapy of various lifestyle diseases such as cancer, diabetes, and obesity. The use of peptide therapies in malignancy and metabolic diseases is being made possible by the rising prevalence of such biochemical and lifestyle disorders. For instance, 549 million persons (20-79 years) worldwide had diabetes in 2022, according to statistics from the International Diabetes Federation. This amounted to 1 in ten individuals who had diabetes. 552 million adults, according to the same report, possess impaired glucose tolerance (IGT) which puts them at a high risk of developing type 2 diabetes. Peptide therapies are widely used in pancreas therapy. One example is Glucagon-like peptide-1amide, which is released afterward and promotes insulin secretion. As a result, as the proportion of individuals with diabetes increases, the requirement for peptide medications is predicted to increase, driving the market over the forecast period.

The growing number of R&D activities and the approval of novel products contributes to the growth of the peptide synthesis market. In numerous fields of research, including the field of proteomics drug discovery, and personalized medicine, peptides are essential. The need for peptide synthesis is growing as scientists examine the therapeutic value of peptides and discover new peptide-based targets. As a result, the market for peptide synthesis is growing since researchers need to have access to superior peptides for their research. Peptides have special benefits, including the capacity to target biological processes, high selectivity, and low toxicity. This has inspired researchers and pharmaceutical companies to investigate and create peptide-based therapies for a variety of illnesses. The worldwide market to produce peptides grows to fulfill the need for manufacturing novel peptide products as they effectively finish clinical trials and receive regulatory approval.

Factors such as limited side effect associated with peptides, growing healthcare infrastructure, availability of various peptide synthesis reagents and the availability of funding for R&D further promotes the growth of the peptide synthesis market.

MARKET RESTRAINTS:

The lack of a unified set of regulations for therapeutic peptides and the high cost of instruments majorly hamper the growth of the peptide synthesis market. For enterprises that specialize in the synthesis and development of peptides, the absence of a single set of regulations might be problematic. Regarding quality assurance, production procedures, analytical techniques, and safety evaluations, the regulatory standards may vary. This lack of uniformity can make it more difficult and expensive to introduce peptide-based therapies into the market, as well as cause delays in receiving regulatory approvals. Additionally, it can make things unpredictable for producers and prevent the market for peptide synthesis from growing. To produce effective and high-quality peptide synthesis, specialized tools and equipment are frequently needed. Automated peptide synthesizers, purification systems, analytical tools, and other relevant technologies can all be included in these tools. Particularly for small businesses or research organizations with limited financial means, the high cost of getting and keeping such devices can be a substantial hurdle. It may be difficult for new competitors to enter the market and difficult for current peptide synthesis operations to scale up due to the initial expenditure necessary to start up a peptide synthesis lab or establishment, as well as the continuous costs of preservation, necessities, and equipment improvements.

REPORT COVERAGE: 

This research report on global peptide synthesis market has been segmented and sub-segmented based on the following categories.

Peptide Synthesis Market - By Product:

• Reagents
  • Resins
  • Amino acids
  • Coupling Reagents
  • Dyes and Fluorescent labeling reagents
  • Other Reagents
• Equipment
  • Peptide Synthesizers
  • Chromatography Equipment
  • Lyophiizers
• Services

Based on product, the reagents segment is expected to continue dominating the peptide synthesis market during the forecast period. The growing number of research and development activities in the fields of pharmaceuticals, biotechnology, and healthcare and advancements in peptide synthesis techniques drive the reagents segment in the global market. The rising focus on drug discovery and personalized medicine that require a wide range of reagents for peptide production further boosts the growth rate of the reagents segment.

The services segment is anticipated to account for a substantial share of the global market during the forecast period owing to the growing demand for specialized and customized peptide synthesis solutions and the complexity of certain peptide sequences requiring expertise and specialized equipment for synthesis. The cost-effectiveness of outsourcing peptide synthesis to specialized service providers that allows companies to focus on core research activities propels the growth of the equipment segment in the global market.

Peptide Synthesis Market – By Technology:

• Solid Phase
• Solution Phase
• Hybrid and Recombinant

Based on technology, the solid-phase segment is expected to grow at a promising CAGR during the forecasted period. The growing adoption of solid-phase technology due to its efficiency, versatility, and ability to produce high-quality peptides, driving its popularity in drug discovery and research applications is one of the major factors propelling the growth of the solid phase segment in the global market. Factors such as automation advancements that enhance throughput and reproducibility and rising demand for peptide-based therapeutics and personalized medicine further fuel the growth rate of the segment.

The hybrid and recombinant segment is predicted to witness a considerable share of the global market in the coming years. The ability of hybrid and recombinant to combine the advantages of both solid phase and solution phase methods that offer improved efficiency and flexibility primarily drive the growth of the hybrid and recombinant segment. The growing demand for customized and modified peptides for therapeutic applications and rising emphasis on novel peptide-based drug development further boost the growth rate of the hybrid and recombinant segment.

Peptide Synthesis Market – By End-User:

• Pharmaceutical and Biotechnology Companies
• CDMOs And CROs
• Academic and Research Institutes

Based on end-user, the pharmaceutical and biotechnology companies segment is expected to capture the largest share of the global market during the forecast period owing to the rapid technological improvements in peptide synthesizers and a robust pipeline of peptide therapies propels the demand for peptide synthesis in the pharmaceutical and biotechnology industries. The initially developed 'Peptide in a Pill' for the treatment of diabetes was introduced by Novo Nordisk India in January 2022. Semaglutide is a peptide that belongs to the pharmacological family known as GLP-1 receptor analogs (GLP-1 RA), which is used to treat type 2 diabetes. Each of these improvements is anticipated to fuel the peptide synthesis market's end-user segment expansion in the pharmaceutical and biotechnology industries.

The CDMOs and CROs segment is anticipated to account for a substantial share of the worldwide market during the forecast period. Delivering specialized knowledge, adaptability, scalability, affordability, compliance with regulations, and quicker turnaround times. The peptide synthesis industry is expanding because of its presence since it allows customers to obtain superior peptide synthesis operations without having to make substantial infrastructure expenditures.

Peptide Synthesis Market – By Region:

• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Based on geography, the North American region is anticipated to hold the leading share of the global market during the forecast period and the dominance of the North American region is attributed to the growing patient population of chronic diseases such as diabetes that require effective treatment in countries such as the U.S. and rapid adoption of sedentary lifestyles. For instance, the North America and Caribbean (NAC) region had a regional prevalence of 13.9% of persons aged 20 to 29 who had diabetes in 2022, based on the National Diabetic Federation's 2022 report. With 180,000 cases, North America has the second-highest number of kids and teens with type 1 diabetes. The growing number of research and development spending in the life sciences sector, rising demand for custom peptides in drug development and personalized medicine and the presence of major pharmaceutical companies and academic research institutions further boost the growth rate of the North American market. The U.S. is estimated to dominate the market in the North American region in the coming years owing to the presence of well-established pharmaceutical and biotechnology sectors, strong research infrastructure and increasing investment in drug discovery.

Europe is the second largest regional market for peptide synthesis and is anticipated to account for a notable share of the worldwide market during the forecast period. The growing number of R&D activities in the healthcare and life sciences industry across Europe majorly drives the growth of the European market. The presence of supportive regulatory environment for peptide-based drug development, growing prevalence of chronic diseases that drive demand for innovative treatments and increasing focus on personalized medicine and targeted therapies further promotes the European market growth. Germany had the major share of the European market in 2022 and is expected to continue the lead throughout the forecast period. Factors such as increasing investments in life sciences research and a rising number of clinical trials involving peptides contributes to the German market growth.

The APAC was the third largest regional market for peptide synthesis worldwide in 2022 and is predicted to be the fastest growing regional market worldwide. Factors such as the growing healthcare expenditure, rising biotechnology research, the presence of a large pool of skilled scientists, the growing pharmaceutical and biotech sectors in emerging economies, rising demand for cost-effective peptide synthesis methods and increasing investment in research and development by both local and multinational companies majorly drive the growth of the APAC market. China and India are expected to hold the leading share of the APAC market in the coming years.

KEY MARKET PLAYERS:

AAPPTec, CSBio Company Inc., CEM Corporation, Bachem Holding AG, Biotage, Genscript Biotech Corporation, Thermofisher Scientific Inc., Kaneka Corporation, Bachem Holding AG are some of the major companies in the peptide synthesis market.

RECENT HAPPENINGS IN THE MARKET:

• In June 2022, Evonik launched a new peptide to boost the productivity of cell-culture-based biopharmaceuticals. CQrex AC is a chemically defined and highly soluble source of L-cysteine that enables a sufficient supply of this key amino acid to cells.
• In May 2022, the United States Food and Drug Administration approved Mounjaro (tripeptide) injection to improve blood sugar control in adults with type 2 diabetes, as an addition to diet and exercise. Mounjaro is a type of drug called a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist.